Lubiprostone - A novel treatment for irritable bowel syndrome with constipation

Drugs of Today

Volumn 44, Issue 9, 2008, Pages 645-652

  Owen, Richard T ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; DRUG METABOLITE; LUBIPROSTONE; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; AREA UNDER THE CURVE; CELL MEMBRANE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTESTINE CELL; INTESTINE MOTILITY; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; NAUSEA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SECRETION; TREATMENT OUTCOME;

EID: 57649129111     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.9.1269852     Document Type: Review

References (27)

1. Foxx-Orenstein, A. IBS - Review and what's new. Medscape Gen Med 2006, 8(3): 20-35.
2. Drossman, D.A., Corazziari, E., Delvauz, M. et al. Rome III: The Functional Gastrointestinal Disorders. Degnon Associates: McLean 2006, 490-509.
3. American College of Gastrointestinal Functional Gastrointestinal Disorders Task Force. Evidence-based position statement of the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(11 Suppl.): S1-5.
4. Brandt, L.J., Bjorkman, D., Fennerty, M.B. et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97(11 Suppl.): S7-26.
5. Drossman, D.A., Camilleri, M., Mayer, E.A., Whitehead, W.E. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123(6): 2108-31.
6. Camilleri, M., Gorman, H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007, 19(7): 545-52.
7. Dunlop, S.P., Hebden, J., Campbell, E. et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2006, 101(6): 1288-94.
8. Marshall, J.K., Thabane, M., Gorg, A.X., Clark, W., Meddings, J., Collins, S.M.; WEL Investigators. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol 2004, 20(11-12): 1317-22.
9. Amitiza® U.S. prescribing information. Available at: http://www.amitiza.com.
10. Lacy, B.F., Levy, L.C. Lubiprostone: A chloride channel activator. J Clin Gastroenterol 2007, 41(4): 345-51.
11. Lipecka, J., Bali, M., Thomas, A., Fanen, P., Edelman, A., Fritsch, J. Distribution of ClC-2 chloride channels in rat and human epithelial tissues. Am J Physiol Cell Physiol 2002, 282: C805-16.
12. Ueno, R., Osama, H., Habe, T., Engelke, K., Pachen, M. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology 2004, 126(4 Suppl. 2): A-298. Abst M1109.
13. Cuppoletti, J., Malinowska, D.H., Tewart, K.P. et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004, 287(5): C1173-83.
14. Moeser, A.J., Nighot, P.K., Engelke, K.J., Ueno, R., Blikslager, A.T. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist if the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007, 292(2): G647-56.
15. Moeser, A.J., Nighot, P.K., Roerig, B., Ueno, R., Blikslager, A.T. Comparison of mucosal reparative responses of lubiprostone and polyethylene glycol (PEG) laxative in ischemic-injured porcine ileum. Gastroenterology 2007, 132(4 Suppl. 2): A-191. Abst. S1186.
16. Johanson, J., Wahle, A., Ueno, R. Efficacy and safety of lubiprostone in a subgroup of constipation patients diagnosed with irritable bowel syndrome with constipation (IBS-C). Am J Gastroenterol 2006, 101(2 Suppl.): S491. Abst. 1270.
17. Johanson, J.F., Drossman, D.A., Panas, R., Wahle, A., Ueno, R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol 2008, 27(8): 685-96.
18. Drossman, D.A., Chey, W., Panas, R., Wahle, A., Scott, C., Ueno, R. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): Data from two twelve-week randomized, placebo-controlled, double-blind trials. Gastroenterology 2007, 132(7): 2586-7.
19. Chey, W.D., Drossman, D.A., Scott, C., Panas, R.M., Ueno, R. What symptoms drive global symptom improvement with lubiprostone in patients with irritable bowel syndrome and constipation? Gastroenterology 2008, 134(4 Suppl. 1): A-28. Abst. S157.
20. Patrick, D.L., Drossman, D.A., Frederick, I.O., DiCesare, J., Puder, K.L. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig Dis Sci 1998, 43(2): 400-11.
21. Drossman, D.A., Chey, W.D., Scott, C., Panas, R.M., Ueno, R. Health related quality of life in adults with irritable bowel syndrome with constipation: Results of a combined analysis of two phase 3 studies with lubiprostone. Gastroenterology 2008, 134(4 Suppl. 1): A-469. Abst. T1036.
22. Chey, W.D., Saad, R.J., Panas, R.M., Wahle, A., Ueno, R. Discontinuation of lubiprostone treatment for irritable bowel syndrome with constipation is not associated with symptom increase or recurrence: Results from a randomized withdrawal study. Gastroenterology 2008, (4 Suppl. 2): A-401. Abst. M1706.
23. Chey, W.D., Drossman, D.A., Scott, C., Panas, R.M., Ueno, R. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 2008, 134(4 Suppl. 1): A-215. Abst. S1272.
24. Johanson, J.F., Morton, D., Geenen, J., Ueno, R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008, 103(1): 170-7.
25. Johanson, J.F., Gargano, M.A., Holland, P.C. et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (CLC-2) activator for the treatment of constipation: Data from a 4-week phase III study. Am J Gastroenterol 2005, 100(9 Suppl.):S324-5. Abst. 884.
26. Ueno, R., Hiroyoshi, O., Engelke, K.J. Effect of lubiprostone on morphine induced constipation and analgesia. Gastroenterology 2006, 130(4 Suppl. 2): A373-4. Abst. M1810.
27. Sucampo Pharmaceuticals, Inc. Opioid-Induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL). Available at: http://clinicaltrials.gov/ ct2/show/NCT00597428?term=lubiprostone&rank=8.